Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

University of Queensland COVID-19 Vaccine Goes Into Test Production

by Global Biodefense Staff
February 23, 2020
University of Queensland COVID-19 Vaccine Goes Into Test Production

A University of Queensland team has met a key milestone in their fast-tracked research to develop a vaccine for the coronavirus, COVID-19.

In just three weeks, the team of researchers has created their first vaccine candidate in the laboratory and will move immediately into further development before formal pre-clinical testing.

The proof-of-concept milestone comes after the project’s announcement on 24 January as part of the Coalition for Epidemic Preparedness Innovations (CEPI) rapid response program.

UQ Vice-Chancellor and President Professor Peter Høj AC said the team has shown considerable progress in line with the highly accelerated time frame of the rapid response program, and the long hours in the lab have paid off with this achievement.

“There is still extensive testing to ensure that the vaccine candidate is safe and creates an effective immune response, but the technology and the dedication of these researchers means the first hurdle has been passed,” Professor Høj said.

The work in the lab shows the feasibility of using UQ’s ‘molecular clamp’ technology to engineer a vaccine candidate that could be more readily recognised by the immune system, triggering a protective immune response.

The next stage is to produce this on a larger scale needed for additional testing, to determine its effectiveness against the virus.

Researchers said the early research had gone ‘as expected’ and the material created had the properties which allowed the team to proceed with vaccine development.

The group continues to work to a much-accelerated timetable to keep on track for investigational clinical testing after the middle of the year.

UQ is one of only three programs globally, and the only one in Australia, initiated by the Coalition for Epidemic Preparedness Innovations (CEPI), leveraging ‘rapid response’ platforms in response to the novel coronavirus outbreak.

Tags: COVID-19Drug DevelopmentEditor PickPublic Health EmergencySARS-CoV-2Vaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy